Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference

Company Overview - Actinium Pharmaceuticals, Inc. is a pioneer in the development of targeted radiotherapies aimed at improving patient outcomes [3] - The company is advancing its lead product candidate, Actimab-A, which targets CD33 and is being developed as a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies [3] - Actinium holds 230 patents and patent applications, including several related to the manufacture of the isotope Ac-225 in a cyclotron [3] Product Development - Actimab-A has shown potential activity in relapsed and refractory AML patients when combined with the chemotherapy CLAG-M, achieving high rates of Complete Remissions (CR) and improved survival outcomes [3] - The company is advancing Actimab-A to a Phase 2/3 trial and is collaborating with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) [3] - The first clinical trial under the CRADA will evaluate a triplet combination of Actimab-A, Venetoclax, and ASTX-727 in frontline AML patients [3] Future Initiatives - Iomab-ACT, a next-generation conditioning candidate, is being developed to enhance patient access and outcomes for cell and gene therapies [3] - Iomab-B is an induction and conditioning agent for bone marrow transplant in patients with relapsed/refractory AML, for which Actinium is seeking a strategic partner in the U.S. [3] - The company's R&D efforts are also focused on advancing several preclinical programs for solid tumor indications [3] Conference Participation - Actinium will participate in the 37th Annual Roth Conference from March 16th to 18th, 2025, with management available for one-on-one meetings on March 17th and 18th [1][2]